Ginger extract inhibits beta-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes

J Altern Complement Med. 2004 Dec;10(6):1009-13. doi: 10.1089/acm.2004.10.1009.

Abstract

Introduction: Neuritic plaques, a neuropathologic hallmark of Alzheimer's disease, are extracellular deposits of beta-amyloid peptides (Abeta). In the central nervous system neuritic plaques are surrounded by activated microglial cells expressing proinflammatory cytokines, chemokines, and neurotoxic mediators. Long-term activation of microglial cells is suspected to contribute to the neuron loss in Alzheimer's disease.

Objective: This study was conducted to determine whether a ginger (Zingiber officinale and Alpinia galanga) extract (GE) can dampen the activation of THP-1 cells by lipopolysaccharide, proinflammatory cytokines, and fibrillar amyloid peptide Abeta(1-42), a major component of neuritic plaques.

Methods: THP-1 cells, a human monocytic cell line with properties similar to human microglial cells, were incubated with GE or control medium alone for 1 hour, and then with reincubated lipopolysaccharide (LPS), tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) or fibrillar Abeta(1-42) for an additional hour. The extent of THP-1 cell activation was determined by measuring mRNA levels of TNF-alpha and IL-1beta, cyclooxygenase-2 (COX-2), macrophage inflammatory protein 1alpha (MIP-1alpha), monocyte chemoattractant protein-1 (MCP-1), and interferon-gamma inducible protein 10 (IP-10).

Results: The results document that the GE used in this study inhibits LPS, cytokine, and amyloid Abeta peptide-induced expression of the proinflammatory genes TNF-alpha, IL-1beta, COX-2, MIP-alpha, MCP-1, and IP-10. The data provide experimental evidence that ginger can inhibit the activation of human monocytic THP-1 cells by different proinflammatory stimuli and reduce the expression of a wide range of inflammation-related genes in these microglial-like cells.

Conclusions: The findings suggest that GE may be useful in delaying the onset and the progression of neurodegenerative disorders involving chronically activated microglial cells in the central nervous system.

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Amyloid beta-Peptides / metabolism*
  • Cell Culture Techniques
  • Chemokine CCL2 / antagonists & inhibitors
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokine CXCL10
  • Chemokines / antagonists & inhibitors*
  • Chemokines, CXC / antagonists & inhibitors
  • Cyclooxygenase 2
  • Cytokines / antagonists & inhibitors*
  • Dose-Response Relationship, Drug
  • Gene Expression Regulation / drug effects
  • Humans
  • Interleukin-1 / antagonists & inhibitors
  • Lipopolysaccharides / antagonists & inhibitors
  • Macrophage Inflammatory Proteins / antagonists & inhibitors
  • Membrane Proteins
  • Monocytes / drug effects*
  • Monocytes / metabolism
  • Peptide Fragments / metabolism*
  • Plant Extracts / pharmacology
  • Plaque, Amyloid / drug effects*
  • Plaque, Amyloid / metabolism
  • Prostaglandin-Endoperoxide Synthases / drug effects
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Zingiber officinale*

Substances

  • Amyloid beta-Peptides
  • Chemokine CCL2
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokine CXCL10
  • Chemokines
  • Chemokines, CXC
  • Cytokines
  • Interleukin-1
  • Lipopolysaccharides
  • Macrophage Inflammatory Proteins
  • Membrane Proteins
  • Peptide Fragments
  • Plant Extracts
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • amyloid beta-protein (1-42)
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases